This page contains a Flash digital edition of a book.
The Crohn’s and Colitis Foundation of Canada’s (CCFC) commitment to finding a cure for Inflammatory Bowel Disease (IBD) and improving the lives of those with IBD is stronger than ever. Canada is the home to many of the world’s top IBD scientists. Thanks to the intensive world-class research funded by the CCFC, our researchers are making important progress on every front – from understanding the basic mechanisms, epidemiology, and genetics to developing new treatments for individuals living with Crohn’s disease (CD) and ulcerative colitis (UC).


In fiscal year 2011/12, the CCFC invested more than $5.4 million in top-calibre IBD research. The grants cover a wide variety of research initiatives including triggers of inflammation, genetics, and microbe interactions. The CCFC also supports some of the most progressive and innovative projects that bring together the finest scientific minds in the field to find new approaches and treatments for IBD.


Through partnerships with the Canadian Institutes of Health Research (CIHR), Canadian Association of Gastroenterology (CAG) and provincial granting agencies, the CCFC has leveraged its investments to train 31 future IBD researchers, encouraging them to pursue careers in IBD research, and support additional IBD-related research.


The CCFC is pushing the dial on translating research into outcomes through a new research


partnership with biotech company, Vertex Phamaceuticals, in conjunction with the Universities of Sherbrooke, Toronto and McMaster. This cutting-edge collaboration represents a unique business model which will improve access to many of the most exciting emerging technologies in the world and help accelerate our understanding of disease, and subsequently, the discovery, development and commercialization of new medicines for IBD.


We hope you enjoy learning about our research progress in this edition of the Research Report and we thank you for your ongoing support and encouragement. Together, we will continue to make significant progress in research and care and make IBD a thing of the past.


Warmest wishes,


John Wallace, PhD Chair, Scientific & Medical Advisory Council


Aida Fernandes, MBA Chief Science & Education Officer


3 | RESEARCH REPORT 2012


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24